A Selective PPARγ modulator, Pemafibrate Suppressed NLRP3 Inflammasome Activation Both in Liver and Heart in a Model of “Steatohepatitis-Related Cardiomyopathy”
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA733225 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR14670412.fastq.gz | Fastqsanger.gz | |||
| SRR14670413.fastq.gz | Fastqsanger.gz | |||
| SRR14670414.fastq.gz | Fastqsanger.gz | |||
| SRR14670415.fastq.gz | Fastqsanger.gz | |||
| SRR14670416.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 6 |
Similar Datasets
Project description:It has been recently reported that the patients with non-alcoholic fatty liver diseases (NAFLD) had accompanied with cardiac dysfunction. However, an animal model of steatohepatitis related cardiomyopathy has not been reported. In the current study, we have developed a mouse model of steatohepatitis-related cardiomyopathy and examined whether a selective PPARα modulator, pemafibrate would improve both steatohepatitis and cardiomyopathy. C57Bl/6 male mice were fed 1. normal chow diet (C group), 2. high fat/high cholesterol/high sucrose/bile acid diet (N group), or 3. N with pemafibrate 0.1 mg/kg (NP group) for three or eight weeks, respectively. Cardiac function was evaluated by ultra-high magnetic field 7-Tesla magnetic resonance imaging (7T-MRI). Even at the eight weeks, we have detected cholesterol crystals, free cholesterol accumulation in liver, followed by macrophage infiltration and fibrosis as wells as activation of NLRP3, caspase-1 and IL-1βmRNA. At the same time in heart, the ratio of heart to body was increased in N group compared to C group. Left ventricular (LV) ejection fraction (LVEF) was moderately decreased in N group compared to C group (50.2±2.8 vs 59.8±2.1, p<0.05). LV circumferential strain and radial strain are focally attenuated in N group, suggesting the early lesion of myocardial damages. mRNA expression of Nlrp3, Caspase1 and Il1b were enhanced in N group, followed by increased protein levels of Caspase-1 and Asc. Rna-sequence analysis revealed that NOD-like receptor and PI3 kinase-AKT pathways were up-regulated, suggesting hypertrophic phenotypes. in N group. Importantly, NLRP3 inflammasome activation were suppressed both in liver and heart in NP group, suggesting pemafibrate had the beneficial effect on steatohepatitis and cardiomyopathy. In addition, four week treatment by pemafibrate improved steatohepatitis and cardiomyopathy after development for eight week. We have first developed the animal model of steatohepatitis-related cardiomyopathy, characterized by the activation of NLRP3 inflammasome pathway both in liver and heart. Steatohepatitis-related cardiomyopathy displayed moderate reduction of LVEF and focal impairment of LV strain by 7T-MRI. Pemafibrate suppressed steatohepatitis, hepatic fibrosis and cardiomyopathy.
2022-02-23 | GSE175708 | GEO
Project description:This study investigates the role of DDX3X SUMOylation in the activation of the NLRP3 inflammasome during sepsis. We demonstrate that SUMOylation of DDX3X, regulated by the SUMO protease SENP1, is a crucial trigger for NLRP3 inflammasome activation. In endotoxemia and sepsis models, the absence of SENP1 in macrophages and mice led to increased NLRP3 inflammasome activation. Mechanistically, DDX3X SUMOylation promoted the interaction of NLRP3 at lysine 118, inhibiting K48-conjugated ubiquitination and subsequent degradation of NLRP3 by the deubiquitinase OTUD6A, resulting in enhanced oligomerization of NLRP3. In murine adoptive transfer experiments, macrophages expressing the SUMOylation-inhibiting mutation DDX3X-K118R suppressed NLRP3 inflammasome activation, providing protection against LPS-induced inflammatory lung injury. These findings suggest that SENP1-mediated DDX3X deSUMOylation regulates NLRP3 inflammasome activation, offering a potential therapeutic avenue to mitigate NLRP3-induced inflammation.
2025-03-06 | PXD060598 | Pride
Project description:Inflammasome, activated by pathogen-derived and host-derived danger signals, constitutes a multimolecular signaling complex that serves as a platform for caspase-1 (CASP1) activation and interleukin-1beta (IL1B) maturation. The activation of NLRP3 inflammasome requires two-step signals. The first “priming” signal (Signal 1) enhances gene expression of inflammasome components. The second “activation” signal (Signal 2) promotes the assembly of inflammasome components. Deregulated activation of NLRP3 inflammasome contributes to the pathological processes of Alzheimer’s disease (AD) and multiple sclerosis (MS). However, at present, the precise mechanism regulating NLRP3 inflammasome activation and deactivation remains largely unknown. By genome-wide gene expression profiling, we studied the molecular network of NLRP3 inflammasome activation-responsive genes in a human monocyte cell line THP-1 sequentially given two-step signals. We identified the set of 83 NLRP3 inflammasome activation-responsive genes. Among them, we found the NR4A nuclear receptor family NR4A1, NR4A2, and NR4A3, the EGR family EGR1, EGR2, and EGR3, the IkappaB family NFKBIZ, NFKBID, and NFKBIA as a key group of the genes that possibly constitute a negative feedback loop for shutting down inflammation following NLRP3 inflammasome activation. By molecular network analysis, we identified a complex network of NLRP3 inflammasome activation-responsive genes involved in cellular development and death, and immune and inflammatory responses, where transcription factors AP-1, NR4A, and EGR serve as a hub. Thus, NLRP3 inflammasome activation-responsive genes constitute the molecular network composed of a set of negative feedback regulators for prompt resolution of inflammation. To load the Signal 1 (S1), THP-1 cells were incubated for 3 hours in the culture medium with or without inclusion of 0.2 microgram/ml lipopolysaccharide (LPS). To load the Signal 2 (S2), they were incubated further for 2 hours in the culture medium with inclusion of 10 microM nigericin sodium salt dissolved in ethanol or the equal v/v% concentration of ethanol (vehicle), followed by processing for microarray analysis on Human Gene 1.0 ST Array (Affymetrix).
2014-07-01 | E-GEOD-58959 | biostudies-arrayexpress
Project description:Musk from male deer (genus Moschus) is used in traditional Chinese medicine for thousands of years due to its anti-inflammatory effects. Muscone, as the main substance of musk, is used in chronic inflammation after myocardial infarction and susceptibility to ventricular arrhythmia by means of controlling inflammation. And previous studies reveal that muscone has a bioactivity of anti-NLRP3 inflammasome activation especially. However, how muscone suppress NLRP3 inflammasome activation is still unclear. In the current study, LPS-primed peritoneal macrophages were employed for validation of muscone suppressing NLRP3 inflammasome activation in vitro. Secondly, we found the occurrence of mitophagy in muscone treatment group by means of RNA-seq. Thirdly, we conducted fluorescence co-localization and electron microscopic analysis to verify whether muscone promote mitophagy during NLRP3 inflammasome activation. Next, we used LPS-induced sepsis mice to examine muscone promoting mitophagy in vivo. Finally, we further inquired the target of muscone promoting mitophagy with help of docking tools. We found that muscone suppressed NLRP3 inflammasome activation both in priming and activation stages in vitro. For priming stage, muscone downregulated the production of NLRP3 and pro-IL-1β with inhibiting NF-κB signaling pathway. For activation stage, muscone disturbed assembly of NLRP3 inflammasome with suppressing ASC oligomerization, interaction of ASC-pro-caspase1. Based on RNA-seq data, we speculated that muscone may promote mitophagy during NLRP3 inflammasome activation. Then we found evidences that muscone promoted mitophagy both in NLRP3 inflammasome activated macrophages and LPS-induced sepsis mice. Finally, molecular docking results displayed that muscone had strong hydrophobic interaction with TSPO, which may one of reasons for muscone promoting mitophagy. Muscone promoted mitophagy both in NLRP3 inflammasome activated macrophages and LPS-induced sepsis mice. Muscone shows a superb potential as a NLRP3 inflammasome inhibitor and a mitophagy agonist for further optimization of structure and application in clinic in trap future.
2026-07-01 | GSE313142 | GEO
Project description:Fatty acid synthase (FASN) catalyzes key steps in de novo lipogenesis and has been implicated in inflammatory and metabolic disorders. Here we show that FASN expression is elevated in gingival tissues from aged individuals and patients with periodontitis. Using a ligature-induced periodontitis (LIP) model, pharmacological inhibition of FASN with C75 attenuated alveolar bone loss, reduced inflammatory cytokines and cell death in gingival crevicular fluid, and suppressed NLRP3 inflammasome activation in gingival tissues. Mechanistically, FASN inhibition led to substrate availability for NLRP3 palmitoylation, selectively impairing its interaction with ASC and consequently disrupting inflammasome assembly. Furthermore, enhanced palmitoylated NLRP3 was detected in gingival tissues upon LIP induction, also under obese-prone conditions, suggesting a novel disease-associated modification. Collectively, these findings uncover a previously unrecognized FASN–NLRP3 palmitoylation axis that regulates inflammasome activation in periodontitis and its associated high-risk metabolic states. Therapeutic targeting FASN may thus offer a promising strategy to ameliorate inflammasome-driven inflammation in periodontitis and its complications.
2026-08-31 | GSE306998 | GEO
Project description:Fatty acid synthase (FASN) catalyzes key steps in de novo lipogenesis and has been implicated in inflammatory and metabolic disorders. Here we show that FASN expression is elevated in gingival tissues from aged individuals and patients with periodontitis. Using a ligature-induced periodontitis (LIP) model, pharmacological inhibition of FASN with C75 attenuated alveolar bone loss, reduced inflammatory cytokines and cell death in gingival crevicular fluid, and suppressed NLRP3 inflammasome activation in gingival tissues. Mechanistically, FASN inhibition led to substrate availability for NLRP3 palmitoylation, selectively impairing its interaction with ASC and consequently disrupting inflammasome assembly. Furthermore, enhanced palmitoylated NLRP3 was detected in gingival tissues upon LIP induction, also under obese-prone conditions, suggesting a novel disease-associated modification. Collectively, these findings uncover a previously unrecognized FASN–NLRP3 palmitoylation axis that regulates inflammasome activation in periodontitis and its associated high-risk metabolic states. Therapeutic targeting FASN may thus offer a promising strategy to ameliorate inflammasome-driven inflammation in periodontitis and its complications.
2026-08-31 | GSE306997 | GEO
Project description:This experiment was performed to analyze the contribution of NLRP3 inflammasome activation to age-related changes in hippocampal RNA. The hypothesis was that decreased inflammasome activation would reduce hippocampal inflammation. Results indicate that inflammasome knockout animals are protected from age-related changes in hippocampal gene expression Gene expression profiles of young (1 month) and old (21-23 month) wild type, CIAS -/- and ASC -/- mouse hippocampal tissue were compared. Total mRNA was extracted using Trizol.
2013-09-05 | E-GEOD-43034 | biostudies-arrayexpress
Project description:The NLRP3 inflammasome is dysregulated in autoinflammatory disorders caused by inherited mutations and contributes to the pathogenesis of several chronic inflammatory diseases. In this study, we discovered that disulfiram, a safe FDA-approved drug, specifically inhibits the NLRP3 inflammasome, but not the NLRC4 or AIM2 inflammasomes. Disulfiram suppresses caspase-1 activation, ASC speck formation, and pyroptosis induced by several stimuli that activate NLRP3. Mechanistically, NLRP3 is palmitoylated at cysteine 126, a modification required for its localization to the trans-Golgi network and inflammasome activation which was inhibited by disulfiram. Administration of disulfiram to animals inhibited the NLRP3, but not the NLRC4 inflammasome in vivo. Our study uncovers a mechanism by which disulfiram targets NLRP3 and provides a rationale for using a safe FDA-approved drug for the treatment of NLRP3-associated inflammatory diseases.
2024-07-25 | PXD054126 | Pride
Project description:The immune system may respond to engineered nanomaterials (ENM) through inflammatory reactions. The NLRP3 inflammasome responds to a wide range of ENM, and its activation is associated with various inflammatory diseases. The objective of the study was to compare the effects of gold ENM of different shapes on NLRP3 inflammasome activation and related signalling pathways. Differentiated THP-1 cells (wildtype, ASC- or NLRP3-deficient), were exposed to PEGylated gold nanorods, nanostars, and nanospheres. Exposed cells were subjected to gene expression analysis. Nanorods, but not nanostars or nanospheres, showed NLRP3 inflammasome activation. ASC- or NLRP3-deficient cells did not show this effect. Gold nanorod-induced NLRP3 inflammasome activation was accompanied by downregulated sterol/cholesterol biosynthesis, oxidative phosphorylation, and purinergic receptor signalling. In conclusion, the shape and surface chemistry of gold nanoparticles determine NLRP3 inflammasome activation.
2023-05-29 | GSE233641 | GEO
Project description:The NLRP3 inflammasome is linked to sterile and pathogen-dependent inflammation, and its dysregulation underlies many chronic diseases. Mitochondria have been implicated as regulators of NLRP3 inflammasome through multiple mechanisms including generation of mitochondrial ROS. Here we report that mitochondrial electron transport chain (ETC) complexes I, II, III and V inhibitors all prevent NLRP3 inflammasome activation. Ectopic expression of Saccharomyces cerevisiae NADH dehydrogenase (NDI1) or Ciona intestinalis alternative oxidase (AOX), which can respectively complement the functional loss of mitochondrial complex I or III, without generation of ROS, rescued NLRP3 inflammasome activation in the absence of endogenous mitochondrial complex I or complex III function. Metabolomics revealed phosphocreatine (PCr), which can sustain ATP levels, as a common metabolite that is diminished by mitochondrial ETC inhibitors. PCr depletion decreased ATP levels and NLRP3 inflammasome activation. Thus, mitochondrial ETC sustains NLRP3 inflammasome activation through PCr-dependent generation of ATP but a ROS independent mechanism.
2022-03-09 | GSE197606 | GEO